{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:09:01Z","timestamp":1783447741119,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115796","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:51:39Z","timestamp":1697147499000},"page":"115796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Simultaneous quantification of nirmatrelvir\/ritonavir in human serum by LC\u2013HRMS"],"prefix":"10.1016","volume":"237","author":[{"given":"Fenglun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunjin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpba.2023.115796_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00192-8","article-title":"The future of paxlovid for COVID-19","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.jpba.2023.115796_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2023.115796_bib3","doi-asserted-by":"crossref","first-page":"7341493","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","author":"Marzi","year":"2022","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/j.jpba.2023.115796_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolin","year":"2022","journal-title":"Clin. Pharm. Ther."},{"issue":"17","key":"10.1016\/j.jpba.2023.115796_bib5","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism","volume":"23","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.jpba.2023.115796_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.jpba.2023.115796_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.05270522","article-title":"Prescribing nirmatrelvir\/ritonavir for COVID-19 in advanced CKD","volume":"17","author":"Hiremath","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10359","key":"10.1016\/j.jpba.2023.115796_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"#cr-split#-10.1016\/j.jpba.2023.115796_bib9.1","unstructured":"National Health Commission, National Administration of Traditional Chinese Medicine, Guidelines for the diagnosis and treatment of coronavirus disease 2019 (Trial version ninth). Chin J Viral Dis, 12"},{"key":"#cr-split#-10.1016\/j.jpba.2023.115796_bib9.2","doi-asserted-by":"crossref","unstructured":"(03) (2022) 161-169. DOI:10.16505\/j.2095-0136.2022.0023.","DOI":"10.5771\/0340-8574-2022-5-161"},{"key":"10.1016\/j.jpba.2023.115796_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123510","article-title":"Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS\/MS in patients treated for COVID-19","volume":"1212","author":"Martens-Lobenhoffer","year":"2022","journal-title":"J. Chromatogr. B"},{"issue":"11","key":"10.1016\/j.jpba.2023.115796_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5456","article-title":"Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS\/MS and its pharmacokinetic application in healthy Chinese volunteers","volume":"36","author":"Liu","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115796_bib12","unstructured":"General Office of National Health Commission. Regulation for prevention and control of healthcare associated infection of airborne transmission disease in healthcare facilities. WS\/T511\u20132016[EB\/OL]. (2017\u201301-17) [2017\u201305-10]. http:\/\/www.nhfpc.gov.cn\/zhuz\/s9496\/201701\/7e0e8fc6725843aabba8f841f2f585d2.shtm."},{"issue":"9","key":"10.1016\/j.jpba.2023.115796_bib13","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3201\/eid2609.202267","article-title":"Effect of environmental conditions on SARS-CoV-2 stability in human nasal mucus and sputum","volume":"26","author":"Matson","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jpba.2023.115796_bib14","unstructured":"General Office of National Health Commission, Diagnosis and Treatment Protocol for COVID-19 (Trial 8 th Eidition, Revised Version) [EB\/OL]. (2021\u201304-14)[2021\u201308-19]. \u3008http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202008\/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml\u3009."},{"key":"10.1016\/j.jpba.2023.115796_bib15","unstructured":"Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization for Paxlovid. (2022\u201309-30)\/ [2022\u201312-02]. \u3008https:\/\/www.fda.gov\/media\/155050\/download\u3009."},{"key":"10.1016\/j.jpba.2023.115796_bib16","unstructured":"Package Instructions for Combination of Nirmatrelvir Tablets\/Ritonavir Tablets, Approved Chinese Medicine HJ20220006. Date of approval: 2022, 02, 11."},{"issue":"11","key":"10.1016\/j.jpba.2023.115796_bib17","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/v14112540","article-title":"Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir\/ritonavir","volume":"14","author":"Akinosoglou","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jpba.2023.115796_bib18","unstructured":"National Institutes of Health. Coronavirus Disease 2019 (Covid-19) Treatment Guideliness. (2022\u201312-01)\/ [2022\u201312-02]. \u3008https:\/\/www.covid19treatmentguidelines.nih.gov\/\u3009."},{"issue":"4","key":"10.1016\/j.jpba.2023.115796_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cpt.2688","article-title":"Pharmacokinetics of oral nirmatrelvir\/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment","volume":"112","author":"Toussi","year":"2022","journal-title":"Clin. Pharm. Ther."},{"issue":"11","key":"10.1016\/j.jpba.2023.115796_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01229-22","article-title":"Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis","volume":"66","author":"Lingscheid","year":"2022","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:31:10Z","timestamp":1760002270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523005654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":21,"alternative-id":["S0731708523005654"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115796","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of nirmatrelvir\/ritonavir in human serum by LC\u2013HRMS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115796"}}